Linker-specific monoclonal antibodies present a simple and reliable detection method for scFv-based CARNK cells

Linker-specific monoclonal antibodies present a simple and reliable detection method for scFv-based CARNK cells

Blog Article

Chimeric antigen read more receptor (CAR) T cell therapies have demonstrated significant successes in treating cancer.Currently, there are six approved CAR T cell products available on the market that target different malignancies of the B cell lineage.However, to overcome the limitations of CAR T cell therapies, other immune cells are being investigated for CAR-based cell therapies.CAR natural killer (NK) cells can be applied as allogeneic cell therapy, providing an economical, safe, and efficient alternative to autologous CAR T cells.To improve CAR research and future in-patient monitoring of cell therapeutics, a simple, reliable, and versatile CAR detection reagent is crucial.

As most existing CARs contain a single-chain variable fragment (scFv) with either a Whitlow or a G4S linker site, linker-specific monoclonal antibodies (mAbs) can detect a bolia outlet gent broad range of CARs.This study demonstrates that these linker-specific mAbs can detect different CAR NK cells in vitro, spiked in whole blood, and within patient-derived tumor spheroids with high specificity and sensitivity, providing an effective and almost universal alternative for scFv-based CAR detection.Additionally, we confirm that linker-specific antibodies can be used for functional testing and enrichment of CAR NK cells, thereby providing a useful research tool to fast-track the development of novel CAR-based therapies.